John C. Byrd

Cincinnati VA Medical Center — United States

Medicine · Health Sciences

61h-index17.1kcitations201works1.82yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chronic Lymphocytic Leukemia Research(151), Lymphoma Diagnosis and Treatment(132), Immunodeficiency and Autoimmune Disorders(46), Monoclonal and Polyclonal Antibodies Research(25), Acute Lymphoblastic Leukemia research(24)

Publications201 total

Bleximenib or placebo in combination with standard induction and consolidation therapy followed by maintenance for the treatment of patients with newly diagnosed KMT2A-rearranged or NPM1-mutant Acute Myeloid Leukemia eligible for intensive chemotherapy: A double-blind Phase 3 study (HOVON 181 AML / AMLSG 37-25)
Blood·2025· 1 cited
Comprehensive comparison of enzymatic and bisulfite DNA methylation analysis in clinically relevant samples
Clinical Epigenetics·2025· 2 citedOpen Access
Molecular Profiling Identifies CD49d and CD79b as Predictive Markers for Acquired Acalabrutinib Resistance in Patients With Chronic Lymphocytic Leukemia
Hematological Oncology·2024· 3 citedOpen Access
Development of ZE66-0205, a Novel MALT1 Degrader for Treatment of B-Cell Malignancies
Blood·2024· 1 citedOpen Access
Supplementary Figures 1 and 2, Table 1 from A Phase I Dose-Finding Trial of Recombinant Interleukin-21 and Rituximab in Relapsed and Refractory Low Grade B-cell Lymphoproliferative Disorders
2023Open Access
Data from A Phase I Dose-Finding Trial of Recombinant Interleukin-21 and Rituximab in Relapsed and Refractory Low Grade B-cell Lymphoproliferative Disorders
2023Open Access
Supplementary Figures from A Phase I/II Trial of Cetuximab in Combination with Interleukin-12 Administered to Patients with Unresectable Primary or Recurrent Head and Neck Squamous Cell Carcinoma
2023Open Access
Supplementary Figures from A Phase I/II Trial of Cetuximab in Combination with Interleukin-12 Administered to Patients with Unresectable Primary or Recurrent Head and Neck Squamous Cell Carcinoma
2023Open Access
Data from A Phase I Dose-Finding Trial of Recombinant Interleukin-21 and Rituximab in Relapsed and Refractory Low Grade B-cell Lymphoproliferative Disorders
2023Open Access
Supplementary Figures 1 and 2, Table 1 from A Phase I Dose-Finding Trial of Recombinant Interleukin-21 and Rituximab in Relapsed and Refractory Low Grade B-cell Lymphoproliferative Disorders
2023Open Access
Genetic heterogeneity of diffuse large B-cell lymphoma
UNC Libraries·2020· 22 citedOpen Access
Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002
UNC Libraries·2020Open Access
Pharmacokinetics and Tolerability of the Novel Non-immunosuppressive Fingolimod Derivative, OSU-2S, in Dogs and Comparisons with Data in Mice and Rats
The AAPS Journal·2020· 3 citedOpen Access
Contributors
Elsevier eBooks·2020
Genetic heterogeneity of diffuse large B-cell lymphoma
UNC Libraries·2019· 5 citedOpen Access
Correction: First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL
Oncotarget·2019· 2 citedOpen Access
ZUMA-8: A phase 1/2 multicenter study evaluating KTE-X19 in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).
Journal of Clinical Oncology·2019· 8 cited
Modulation of immune checkpoint molecule expression in mantle cell lymphoma
Leukemia & lymphoma/Leukemia and lymphoma·2019· 32 cited
Population pharmacokinetics of lenalidomide in patients with B‐cell malignancies
British Journal of Clinical Pharmacology·2019· 13 citedOpen Access
Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis
British Journal of Haematology·2018· 90 citedOpen Access
page 1 of 11Next →

Frequent Co-authors

Ian W. Flinn(24), Thomas J. Kipps(8), Michael R. Grever(8), Thomas S. Lin(8), Steven Coutré(7), Kristie A. Blum(6), Nyla A. Heerema(6), Susan O’Brien(6), Jennifer R. Brown(6), R. Kanti(6), Richard R. Furman(5), Neil E. Kay(5), Gerard Lozanski(5), Natarajan Muthusamy(5), Amy J. Johnson(4), Don M. Benson(4), Nina D. Wagner‐Johnston(4), David Lucas(4), Donn C. Young(4), Michael J. Keating(3)